SCHEMBL16093733

SCHEMBL16093733

[Ag].[CH]Cn1c(=O)n(C)c(=O)c2c1ncn2C

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 5/20 0.70
PDE4A P27815 4/20 0.70
PDE4B Q07343 4/20 0.70
PDE4C Q08493 4/20 0.70
PDE4D Q08499 4/20 0.70
ADORA2B P29275 10/20 0.69
PIK3CD O00329 1/20 0.63
POLB P06746 1/20 0.63
ADORA3 P0DMS8 1/20 0.63
CNR1 P21554 1/20 0.63
ACHE P22303 1/20 0.63
ADORA1 P30542 1/20 0.63
NTSR1 P30989 1/20 0.63
MC3R P41968 1/20 0.63
NOTUM Q6P988 1/20 0.63
SIRT3 Q9NTG7 1/20 0.63
GDA Q9Y2T3 1/20 0.63
NR2E1 Q9Y466 1/20 0.63
BLM P54132 2/20 0.57
GLA P06280 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16697212 0.84 ADORA2A (0.79) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL4145707 0.83 ADORA2A (0.77) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL21381247 0.83 PDE4A (1.00) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL316760 0.82 ADORA2B (1.00) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL8861588 0.81 PDE4A (0.75) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL23974594 0.80 ADORA2A (0.68) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL515931 0.80 ADORA2A (0.68) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL5411063 0.80 ADORA2A (0.68) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL1200300 0.80 ADORA2A (0.68) ADORA2APDE4APDE4BPDE4CPDE4D
SCHEMBL11675524 0.79 PDE4A (0.71) ADORA2APDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160030476-A1 Compositions, Methods And Devices For Promoting Wound Healing And Reducing Infection IASIS MOLECULAR SCIENCES (US) 2016-02-04 US disclosed
EP-2967076-A2 COMPOSITIONS, METHODS AND DEVICES FOR PROMOTING WOUND HEALING AND REDUCING INFECTION Iasis Molecular Sciences (US) 2016-01-20 EP disclosed
WO-2014153238-A9 COMPOSITIONS, METHODS AND DEVICES FOR PROMOTING WOUND HEALING AND REDUCING INFECTION IASIS MOLECULAR SCIENCES (US) 2014-12-04 WO disclosed
WO-2014153238-A2 COMPOSITIONS, METHODS AND DEVICES FOR PROMOTING WOUND HEALING AND REDUCING INFECTION IASIS MOLECULAR SCIENCES (US) 2014-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160030476-A1 Compositions, Methods And Devices For Promoting Wound Healing And Reducing Infection MMP8, IL1B, MMP1 ADORA2A 2760/4885PDE4A 2212/4885PDE4B 2410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.